STRATA SKIN SCIENCES INC (SSKN) Fundamental Analysis & Valuation

NASDAQ:SSKN • US86272A3059

0.1898 USD
-0.13 (-39.99%)
At close: Feb 18, 2026
0.159 USD
-0.03 (-16.23%)
After Hours: 2/18/2026, 8:03:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SSKN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

SSKN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of SSKN have multiple concerns. SSKN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. SSKN Profitability Analysis

1.1 Basic Checks

  • SSKN had negative earnings in the past year.
  • SSKN had a negative operating cash flow in the past year.
  • SSKN had negative earnings in each of the past 5 years.
  • In multiple years SSKN reported negative operating cash flow during the last 5 years.
SSKN Yearly Net Income VS EBIT VS OCF VS FCFSSKN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

  • SSKN has a worse Return On Assets (-35.94%) than 62.16% of its industry peers.
  • SSKN's Return On Equity of -840.18% is on the low side compared to the rest of the industry. SSKN is outperformed by 84.86% of its industry peers.
Industry RankSector Rank
ROA -35.94%
ROE -840.18%
ROIC N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
SSKN Yearly ROA, ROE, ROICSSKN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • SSKN has a Gross Margin of 57.76%. This is comparable to the rest of the industry: SSKN outperforms 58.92% of its industry peers.
  • SSKN's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SSKN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
SSKN Yearly Profit, Operating, Gross MarginsSSKN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. SSKN Health Analysis

2.1 Basic Checks

  • SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SSKN has more shares outstanding than it did 1 year ago.
  • SSKN has less shares outstanding than it did 5 years ago.
  • SSKN has a worse debt/assets ratio than last year.
SSKN Yearly Shares OutstandingSSKN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SSKN Yearly Total Debt VS Total AssetsSSKN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -11.29, we must say that SSKN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -11.29, SSKN is doing worse than 78.92% of the companies in the same industry.
  • A Debt/Equity ratio of 10.22 is on the high side and indicates that SSKN has dependencies on debt financing.
  • SSKN's Debt to Equity ratio of 10.22 is on the low side compared to the rest of the industry. SSKN is outperformed by 86.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.22
Debt/FCF N/A
Altman-Z -11.29
ROIC/WACCN/A
WACC10.67%
SSKN Yearly LT Debt VS Equity VS FCFSSKN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 0.95 indicates that SSKN may have some problems paying its short term obligations.
  • SSKN has a Current ratio of 0.95. This is amonst the worse of the industry: SSKN underperforms 87.57% of its industry peers.
  • SSKN has a Quick Ratio of 0.95. This is a bad value and indicates that SSKN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of SSKN (0.75) is worse than 85.41% of its industry peers.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.75
SSKN Yearly Current Assets VS Current LiabilitesSSKN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SSKN Growth Analysis

3.1 Past

  • The earnings per share for SSKN have decreased by -0.38% in the last year.
  • Looking at the last year, SSKN shows a decrease in Revenue. The Revenue has decreased by -5.19% in the last year.
  • The Revenue has been growing slightly by 1.22% on average over the past years.
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.14% on average over the next years. This is quite good.
  • Based on estimates for the next years, SSKN will show a small growth in Revenue. The Revenue will grow by 2.63% on average per year.
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue Next Year-7.22%
Revenue Next 2Y-0.28%
Revenue Next 3Y2.63%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SSKN Yearly Revenue VS EstimatesSSKN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
SSKN Yearly EPS VS EstimatesSSKN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

0

4. SSKN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SSKN. In the last year negative earnings were reported.
  • Also next year SSKN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SSKN Price Earnings VS Forward Price EarningsSSKN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SSKN Per share dataSSKN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • SSKN's earnings are expected to grow with 17.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.43%
EPS Next 3Y17.14%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SSKN Dividend Analysis

5.1 Amount

  • No dividends for SSKN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SSKN Fundamentals: All Metrics, Ratios and Statistics

STRATA SKIN SCIENCES INC

NASDAQ:SSKN (2/18/2026, 8:03:01 PM)

After market: 0.159 -0.03 (-16.23%)

0.1898

-0.13 (-39.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-25
Inst Owners19.58%
Inst Owner Change-5.42%
Ins Owners0.18%
Ins Owner Change-0.24%
Market Cap1.12M
Revenue(TTM)30.98M
Net Income(TTM)-11.04M
Analysts85
Price Target7.55 (3877.87%)
Short Float %16.69%
Short Ratio1.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.02%
Min EPS beat(2)-104.6%
Max EPS beat(2)8.56%
EPS beat(4)1
Avg EPS beat(4)-94.34%
Min EPS beat(4)-271.14%
Max EPS beat(4)8.56%
EPS beat(8)2
Avg EPS beat(8)-98.86%
EPS beat(12)4
Avg EPS beat(12)-57.78%
EPS beat(16)7
Avg EPS beat(16)-39.57%
Revenue beat(2)0
Avg Revenue beat(2)-14.84%
Min Revenue beat(2)-17.42%
Max Revenue beat(2)-12.25%
Revenue beat(4)1
Avg Revenue beat(4)-8.34%
Min Revenue beat(4)-17.42%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-8.04%
Revenue beat(12)4
Avg Revenue beat(12)-5.63%
Revenue beat(16)6
Avg Revenue beat(16)-2.84%
PT rev (1m)0%
PT rev (3m)-7.5%
EPS NQ rev (1m)21.58%
EPS NQ rev (3m)-4.88%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.01%
Revenue NQ rev (1m)8.09%
Revenue NQ rev (3m)2.12%
Revenue NY rev (1m)2.3%
Revenue NY rev (3m)-5.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.67
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.26
BVpS0.22
TBVpS-0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.94%
ROE -840.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.76%
FCFM N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score3
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 10.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.81%
Cap/Sales 5.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.95
Quick Ratio 0.75
Altman-Z -11.29
F-Score3
WACC10.67%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)69.64%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%
Revenue Next Year-7.22%
Revenue Next 2Y-0.28%
Revenue Next 3Y2.63%
Revenue Next 5YN/A
EBIT growth 1Y-4.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.21%
EBIT Next 3Y84%
EBIT Next 5YN/A
FCF growth 1Y47.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.99%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%

STRATA SKIN SCIENCES INC / SSKN FAQ

What is the fundamental rating for SSKN stock?

ChartMill assigns a fundamental rating of 1 / 10 to SSKN.


What is the valuation status for SSKN stock?

ChartMill assigns a valuation rating of 0 / 10 to STRATA SKIN SCIENCES INC (SSKN). This can be considered as Overvalued.


How profitable is STRATA SKIN SCIENCES INC (SSKN) stock?

STRATA SKIN SCIENCES INC (SSKN) has a profitability rating of 1 / 10.


Can you provide the financial health for SSKN stock?

The financial health rating of STRATA SKIN SCIENCES INC (SSKN) is 0 / 10.


What is the expected EPS growth for STRATA SKIN SCIENCES INC (SSKN) stock?

The Earnings per Share (EPS) of STRATA SKIN SCIENCES INC (SSKN) is expected to grow by 29.66% in the next year.